[40] Pfeiler G, Konigsberg R, Fesl C, Mlineritsch B, Stoeger H, Singer CF, Postlberger S, Steger GG, Seifert M, Dubsky P, Taucher S, Samonigg H, Bjelic-Radisic V, Greil R, Marth C, Gnant M. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol l2011;29: 2653-9.

[39] Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, Dietze O, Greil R, Jelen A, Sevelda P, Freibauer C, Muller V, Janicke F, Schmidt M, Kolbl H, Rody A, Kaufmann M, Schroth W, Brauch H, Schwab M, Fritz P, Weber KE, Feder IS, Hennig G, Kronenwett R, Gehrmann M, Gnant M. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res l2011;17: 6012-20.

[38] Bago-Horvath Z, Rudas M, Dubsky P, Jakesz R, Singer CF, Kemmerling R, Greil R, Jelen A, Bohm G, Jasarevic Z, Haid A, Gruber C, Postlberger S, Filipits M, Gnant M. Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer. Clin Cancer Res l2011;17: 7828-34.

[37] Meraner V, Giesinger J, Kemmler G, Taucher S, Hubalek M, Weber B, Rumpold G, Sperner-Unterweger B, Holzner B. Development of a screening tool for the identification of psychooncological treatment need in breast cancer patients. Psychooncology l2009;18: 974-83.

[36] Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rucklinger E, Greil R, Marth C. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med l2009;360: 679-91.

[35] Filipits M, Rudas M, Heinzl H, Jakesz R, Kubista E, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Nader A, Stierer M, Gnant MF. Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy. Clin Cancer Res l2009;15: 5888-94.

[34] Taucher S, Steger GG, Jakesz R, Tausch C, Wette V, Schippinger W, Kwasny W, Reiner G, Greil R, Dubsky P, Poestlberger S, Tschmelitsch J, Samonigg H, Gnant M. The potential risk of neoadjuvant chemotherapy in breast cancer patients–results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07). Breast Cancer Res Treat l2008;112: 309-16.

[33] Rudas M, Lehnert M, Huynh A, Jakesz R, Singer C, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Grill R, Stierer M, Gnant MF, Filipits M. Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy. Clin Cancer Res l2008;14: 1767-74.

[32] Mlineritsch B, Tausch C, Singer C, Luschin-Ebengreuth G, Jakesz R, Ploner F, Stierer M, Melbinger E, Menzel C, Urbania A, Fridrik M, Steger G, Wohlmuth P, Gnant M, Greil R. Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17). Breast Cancer Res Treat l2008;112: 203-13.

[31] Dubsky P, Sevelda P, Jakesz R, Hausmaninger H, Samonigg H, Seifert M, Denison U, Mlineritsch B, Steger G, Kwasny W, Stoger H, Bartsch R, Stierer M, Taucher S, Fridrik M, Schippinger W, Greil R, Potter R, Gnant M. Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy. Clin Cancer Res l2008;14: 2082-7.

[30] Potter R, Gnant M, Kwasny W, Tausch C, Handl-Zeller L, Pakisch B, Taucher S, Hammer J, Luschin-Ebengreuth G, Schmid M, Sedlmayer F, Stierer M, Reiner G, Kapp K, Hofbauer F, Rottenfusser A, Postlberger S, Haider K, Draxler W, Jakesz R. Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer. Int J Radiat Oncol Biol Phys l2007;68: 334-40.

[29] Mueller-Holzner E, Frede T, Daniaux M, Ban M, Taucher S, Schneitter A, Zeimet AG, Marth C. Ultrasound-guided core needle biopsy of the breast: does frozen section give an accurate diagnosis? Breast Cancer Res Treat l2007;106: 399-406.

[28] Fitzal F, Sporn EP, Draxler W, Mittlbock M, Taucher S, Rudas M, Riedl O, Helbich TH, Jakesz R, Gnant M. Preoperative core needle biopsy does not increase local recurrence rate in breast cancer patients. Breast Cancer Res Treat l2006;97: 9-15.

[27] Taucher S, Rudas M, Mader RM, Gnant M, Dubsky P, Roka S, Bachleitner T, Kandioler D, Steger G, Mittlbock M, Jakesz R. Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancer. Wien Klin Wochenschr l2004;116: 26-31.

[26] Taucher S, Jakesz R. Survival after surgical treatment of breast cancer. Langenbecks Arch Surg l2004;389: 75-82.

[25] Schoppmann SF, Bayer G, Aumayr K, Taucher S, Geleff S, Rudas M, Kubista E, Hausmaninger H, Samonigg H, Gnant M, Jakesz R, Horvat R. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg l2004;240: 306-12.

[24] Roka S, Rudas M, Taucher S, Dubsky P, Bachleitner-Hofmann T, Kandioler D, Gnant M, Jakesz R. High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS. Eur J Surg Oncol l2004;30: 243-7.

[23] Taucher S, Salat A, Gnant M, Kwasny W, Mlineritsch B, Menzel RC, Schmid M, Smola MG, Stierer M, Tausch C, Galid A, Steger G, Jakesz R. Impact of pretreatment thrombocytosis on survival in primary breast cancer. Thromb Haemost l2003;89: 1098-106.

[22] Taucher S, Rudas M, Mader RM, Gnant M, Sporn E, Dubsky P, Roka S, Bachleitner T, Fitzal F, Kandioler D, Wenzel C, Steger GG, Mittlbock M, Jakesz R. Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer. Breast Cancer Res Treat l2003;82: 207-13.

[21] Taucher S, Rudas M, Mader RM, Gnant M, Dubsky P, Bachleitner T, Roka S, Fitzal F, Kandioler D, Sporn E, Friedl J, Mittlbock M, Jakesz R. Do we need HER-2/neu testing for all patients with primary breast carcinoma? Cancer l2003;98: 2547-53.

[20] Taucher S, Rudas M, Gnant M, Thomanek K, Dubsky P, Roka S, Bachleitner T, Kandioler D, Wenzel C, Steger G, Mittlbock M, Jakesz R. Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy. Endocr Relat Cancer l2003;10: 91-8.

[19] Taucher S, Gnant M, Jakesz R. Preventive mastectomy in patients at breast cancer risk due to genetic alterations in the BRCA1 and BRCA2 gene. Langenbecks Arch Surg l2003;388: 3-8.

[18] Schmid M, Jakesz R, Samonigg H, Kubista E, Gnant M, Menzel C, Seifert M, Haider K, Taucher S, Mlineritsch B, Steindorfer P, Kwasny W, Stierer M, Tausch C, Fridrik M, Wette V, Steger G, Hausmaninger H. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6. J Clin Oncol l2003;21: 984-90.

[17] Rudas M, Filipits M, Taucher S, Stranzl T, Steger GG, Jakesz R, Pirker R, Pohl G. Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy. Breast Cancer Res Treat l2003;81: 149-57.

[16] Pohl G, Rudas M, Taucher S, Stranzl T, Steger GG, Jakesz R, Pirker R, Filipits M. Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy. Breast Cancer Res Treat l2003;78: 97-103.

[15] Jakesz R, Samonigg H, Gnant M, Kubista E, Depisch D, Kolb R, Mlineritsch B, Mischinger HJ, Menzel RC, Steindorfer P, Kwasny W, Tausch C, Stierer M, Taucher S, Seifert M, Hausmaninger H. Significant increase in breast conservation in 16 years of trials conducted by the Austrian Breast & Colorectal Cancer Study Group. Ann Surg l2003;237: 556-64.

[14] Wenzel C, Locker GJ, Schmidinger M, Rudas M, Taucher S, Gnant MF, Jakesz R, Steger GG. Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel+granulocyte colony stimulating factor. Anticancer Drugs l2002;13: 67-74.

[13] Wenzel C, Locker GJ, Pluschnig U, Zielinski CC, Rudas M, Oberhuber G, Gnant MF, Taucher S, Jakesz R, Steger GG. Phase I/II trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancer. Cancer Chemother Pharmacol l2002;50: 155-9.

[12] Dubsky PC, Gnant MF, Taucher S, Roka S, Kandioler D, Pichler-Gebhard B, Agstner I, Seifert M, Sevelda P, Jakesz R. Young age as an independent adverse prognostic factor in premenopausal patients with breast cancer. Clin Breast Cancer l2002;3: 65-72.

[11] Bachleitner-Hofmann T, Pichler-Gebhard B, Rudas M, Gnant M, Taucher S, Kandioler D, Janschek E, Dubsky P, Roka S, Sporn E, Jakesz R. Pattern of hormone receptor status of secondary contralateral breast cancers in patients receiving adjuvant tamoxifen. Clin Cancer Res l2002;8: 3427-32.

[10] Janschek E, Kandioler-Eckersberger D, Ludwig C, Kappel S, Wolf B, Taucher S, Rudas M, Gnant M, Jakesz R. Contralateral breast cancer: molecular differentiation between metastasis and second primary cancer. Breast Cancer Res Treat l2001;67: 1-8.

[09] Huber S, Medl M, Helbich T, Taucher S, Wagner T, Rudas M, Zuna I, Delorme S. Locally advanced breast carcinoma: computer assisted semiquantitative analysis of color Doppler ultrasonography in the evaluation of tumor response to neoadjuvant chemotherapy (work in progress). J Ultrasound Med l2000;19: 601-7.

[08] Gebhard B, Gnant M, Schutz G, Roka S, Weigel G, Kandioler D, Taucher S, Grunberger T, Roth E, Jakesz R, Spittler A. Different transendothelial migration behaviour pattern of blood monocytes derived from patients with benign and malignant diseases of the breast. Anticancer Res l2000;20: 4599-604.

[07] Wenzel C, Schmidinger M, Locker GJ, Taucher S, Gnant M, Jakesz R, Steger GG. [Clinical phase II-evaluation of neoadjuvant, cytostatic combination chemotherapy with docetaxel and epidoxorubicin in female breast cancer patients (T1-4, N0-2, M0)]. Wien Klin Wochenschr l1999;111: 843-50.

[06] Jakesz R, Gebhard B, Gnant M, Taucher S. [Indications and contraindications for breast preservation in patients with breast cancer]. Chirurg l1999;70: 394-9.

[05] Helbich TH, Rudas M, Bohm G, Huber S, Wagner T, Taucher S, Wolf G, Mostbeck GH. Randomized in vitro and in vivo evaluation of different biopsy needles and devices for breast biopsy. Clin Radiol l1999;54: 56-62.

[04] Jakesz R, Taucher S, Gnant M, Gebhard B, Kandioler D, Rudas M, Djavanmard M, Steger G. [Neoadjuvant chemotherapy of patients with breast carcinoma]. Zentralbl Chir l1998;123 Suppl 5: 147-50.

[03] Friedl J, Stift A, Berlakovich GA, Taucher S, Gnant M, Steininger R, Muhlbacher F. Haemophilus parainfluenzae liver abscess after successful liver transplantation. J Clin Microbiol l1998;36: 818-9.

[02] Berlakovich GA, Rockenschaub S, Taucher S, Kaserer K, Muhlbacher F, Steiniger R. Underlying disease as a predictor for rejection after liver transplantation. Arch Surg l1998;133: 167-72.

[01] Helbich TH, Mayr W, Schick S, Youssefzadeh S, Rudas M, Taucher S, Wagner T, Kelkar P, Wolf G, Thurnher M, Mostbeck GH. Coaxial technique: approach to breast core biopsies. Radiology l1997;203: 684-90.